Travere Therapeutics, INC 8-K filings

Travere Therapeutics announced robust second quarter 2026 financial results, highlighted by significant FILSPARI sales growth and strategic pipeline expansion.

Travere Therapeutics, Inc. announced the upcoming retirement of its Chief Accounting Officer, Sandra Calvin, with Vice President, Controller John Torell slated to succeed her.

Travere Therapeutics announced the upcoming retirement of its Chief Research Officer, William Rote, Ph.D., effective February 17, 2027, with Dr. Jula Inrig to assume expanded R&D leadership responsibilities.

Travere Therapeutics has entered into a material definitive agreement, securing an exclusive license from Everest Medicines for the development and commercialization of civorebrutinib outside of China and certain Asian countries.

Travere Therapeutics held its 2026 Annual Meeting of Stockholders, approving an amendment to its 2018 Equity Incentive Plan to increase authorized shares and ratifying the selection of its independent auditor.

Travere Therapeutics has successfully closed a $525 million offering of convertible senior notes due 2032, with a portion of the proceeds earmarked for repurchasing existing 2029 notes.

Travere Therapeutics announced strong first quarter 2026 financial results, driven by significant year-over-year growth in FILSPARI net product sales and the recent FDA approval for FSGS.

Travere Therapeutics announced robust fourth quarter and full year 2025 financial results, driven by significant growth in FILSPARI sales and progress in its rare disease pipeline.

Travere Therapeutics announced the FDA extended the review timeline for its supplemental New Drug Application for FILSPARI in focal segmental glomerulosclerosis to April 13, 2026, due to a Major Amendment.

Travere Therapeutics announced preliminary Q4 and full-year 2025 financial results, highlighted by record FILSPARI sales and progress towards FSGS approval and a pivotal HCU study restart.

Travere Therapeutics reported robust third-quarter 2025 financial results, driven by significant FILSPARI sales growth and strategic financial achievements, including debt retirement and a key milestone payment.

Travere Therapeutics announced the FDA will not require an advisory committee for its FILSPARI supplemental New Drug Application in focal segmental glomerulosclerosis, maintaining a PDUFA target action date of January 13, 2026.

Travere Therapeutics reported strong second quarter 2025 financial results, driven by a 165% year-over-year growth in U.S. net product sales of FILSPARI, alongside significant regulatory and clinical advancements.

Travere Therapeutics' stockholders approved an amendment to the 2018 Equity Incentive Plan, increasing the number of shares available for issuance by 4,000,000, among other proposals at the 2025 Annual Meeting.

Travere Therapeutics announces the FDA's acceptance of its supplemental New Drug Application (sNDA) for FILSPARI in treating focal segmental glomerulosclerosis (FSGS), with a PDUFA target action date set for January 13, 2026.

Travere Therapeutics announces positive Q1 2025 financial results, highlighted by a 182% year-over-year increase in FILSPARI U.S. net product sales and progress in expanding FILSPARI's indications.

Travere Therapeutics announces positive Q1 2025 financial results, highlighted by a 182% year-over-year increase in FILSPARI U.S. net product sales and progress in expanding FILSPARI into FSGS.

Travere Therapeutics and CSL Vifor announce European Commission approval converting conditional marketing approval to standard marketing authorization for FILSPARI in IgAN treatment, leading to a $17.5 million milestone payment.

Travere Therapeutics has submitted a supplemental New Drug Application (sNDA) to the FDA seeking traditional approval and priority review for FILSPARI in the treatment of focal segmental glomerulosclerosis (FSGS).

Travere Therapeutics announces positive Q4 and full-year 2024 financial results, driven by strong FILSPARI sales and provides updates on its clinical programs.

Travere Therapeutics announces plans to submit a supplemental New Drug Application (sNDA) to the FDA for FILSPARI to treat focal segmental glomerulosclerosis (FSGS) based on existing clinical data.

Travere Therapeutics announced preliminary Q4 2024 net product sales of approximately $74 million and provided updates on key clinical and regulatory milestones.

Travere Therapeutics has priced a public offering of 7,812,500 shares of common stock at $16.00 per share, expecting to raise $125 million before expenses.

Travere Therapeutics announced positive third quarter 2024 financial results, highlighted by the full FDA approval and strong sales growth of FILSPARI.

Travere Therapeutics has voluntarily paused enrollment in its Phase 3 HARMONY study for classical homocystinuria (HCU) due to challenges in scaling up manufacturing.

Travere Therapeutics' FILSPARI receives full FDA approval for slowing kidney function decline in adults with primary Immunoglobulin A nephropathy (IgAN), based on positive long-term results from the PROTECT Study.

Travere Therapeutics announced a successful second quarter of 2024, highlighted by significant growth in FILSPARI sales and patient start forms.

Travere Therapeutics' stockholders approved an increase in shares for the 2018 Equity Incentive Plan and elected ten directors at the company's 2024 Annual Meeting.

Travere Therapeutics announced positive first quarter 2024 financial results, highlighted by increased FILSPARI sales and regulatory advancements.

Travere Therapeutics and CSL Vifor have secured conditional marketing authorization from the European Commission for FILSPARI to treat adults with primary IgA nephropathy.